• Torin2: mTOR Signaling and Cancer Research

  2026-10-06

  A source-grounded overview of Torin2 as an mTOR inhibitor in cancer research, covering its reported selectivity, conceptual uses in signaling and apoptosis studies, medullary thyroid carcinoma findings, and the limits of connecting Torin2 biology with recent RNA polymerase II research.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-10-06

  The reference study identifies O-GlcNAcylation as a mechanistic bridge between Wnt3a signaling, glucose metabolism, and osteoblast-mediated bone formation. Its evidence places PDK1 stabilization and aerobic glycolysis downstream of Wnt, while also showing why metabolic control may be essential for Wnt-driven bone anabolism and fracture repair.

• Beyond Viability: Interpreting Cancer Drug Responses

  2026-10-05

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, clarifying that growth arrest and cell death are related but non-equivalent components of an anticancer response. This framework supports more careful interpretation of time-dependent drug effects while highlighting the limits of treating a single viability readout as a complete measure of therapeutic activity.

• Foretinib (GSK1363089): Interpreting Cancer Drug Response

  2026-10-05

  Foretinib (GSK1363089) is a multikinase research tool whose effects span signaling, proliferation, motility, and metastasis. This article presents an evidence-centered framework for interpreting those outcomes without confusing biochemical potency, tumor cell growth inhibition, and cell death.

• Natural Product Screening for Cryptosporidium

  2026-10-04

  The 2024 study of Cryptosporidium parvum AdhE provides a useful proof of concept for connecting enzyme inhibition with parasite-growth suppression, but it does not establish clinical efficacy or validate any particular commercial library. This overview compares the study’s biochemical, cellular and cytotoxicity findings with the supplier-described scope of the DiscoveryProbe™ Natural Product Library Plus (Catalog No. L1039P). It also explains why the reported results support further target-focused natural product screening while leaving important questions about mechanism, compound identity, selectivity, pharmacology and applicability to other Cryptosporidium species unresolved.

• BBB-Crossing LNPs for CNS mRNA Delivery

  2026-10-03

  Wang and colleagues developed a library of blood–brain-barrier-crossing lipids and identified lipid nanoparticles that delivered mRNA to neurons and astrocytes across broad mouse brain regions. The study provides a platform-level advance for central nervous system delivery, while its ex vivo and animal evidence still requires validation in disease models and human studies.

• AG-221 Enasidenib in IDH2-Mutant AML Research

  2026-10-02

  Build a mechanism-led workflow for studying mutant IDH2, 2-hydroxyglutarate reduction, and leukemia cell differentiation with AG-221 (Enasidenib). The workflow pairs pharmacologic IDH2 inhibition with CD44 and metabolic readouts to distinguish target engagement from nonspecific cytotoxicity.

• Thiamet G: O-GlcNAcase Inhibitor Guide

  2026-10-01

  Thiamet G is a selective O-GlcNAcase inhibitor that increases cellular O-GlcNAc levels and reduces disease-associated tau phosphorylation in experimental systems. Its reported activity spans cultured cells and animal models, but product specifications should not be interpreted as universal dosing protocols or clinical evidence.

• Stable Isotope UHPLC-MS/MS for Methylated Nucleosides

  2026-10-01

  The 2024 Analytical Chemistry study developed a stable isotope-diluted UHPLC–ESI-MS/MS workflow for accurate measurement of 12 purine ribonucleosides, including 10 methylated species. Enhanced ionization, solid-phase cleanup, and chromatographic separation of isomers enabled sensitive intracellular quantification relevant to RNA modification research, cancer metabolism studies, and biomarker discovery.

• Cyclopamine: An Assay-First Hedgehog Strategy

  2026-09-30

  Cyclopamine is a Hedgehog signaling inhibitor with applications spanning pathway biology, cancer research, and developmental toxicology. This assay-first guide shows how to connect Smoothened perturbation with APOC1-informed experiments and defensible interpretation.

• PF-573228 FAK Inhibitor Workflow Guide

  2026-09-30

  PF-573228 is a practical FAK inhibitor for connecting focal-adhesion signaling with matrix mechanics, cancer-cell motility, and endothelial behavior. This workflow guide translates the LAMB1–FAK–MEK1/2 dentinogenesis study into dose, timing, readout, and troubleshooting strategies for reproducible experiments.

• Smo in Honeybees Links Hedgehog Signaling to Olfaction

  2026-09-29

  Guo and colleagues identify and functionally examine Smoothened (Smo) in Apis mellifera, showing that Smo expression is enriched in antennae and associated with olfactory receptor expression, antennal electrophysiology, and odor-guided behavior. The study extends Hedgehog pathway research into insect sensory biology and provides a pharmacological framework for testing how Smo influences olfactory recognition.

• CHIR 99021 Trihydrochloride for Organoids

  2026-09-29

  Use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor to interrogate stem-cell self-renewal, organoid diversification, and insulin-linked biology. This workflow separates concentration, exposure time, and differentiation context so researchers can distinguish pathway activation from nonspecific growth effects.

• Salinomycin for Reliable HCC Cell Assays

  2026-09-28

  This scenario-driven guide explains how Salinomycin (SKU A3785) can support better-designed viability, proliferation, apoptosis, and mechanism-focused assays in hepatocellular carcinoma research. It connects practical solvent and endpoint decisions with published guidance distinguishing relative from fractional viability.

• SGK1, Endothelial Mechanics, and Translation

  2026-09-28

  Endothelial SGK1 connects salt and mineralocorticoid signaling to vascular stiffness through changes in actin organization. This article interprets the mechanistic evidence, explains how EMD638683 can support pathway-focused experiments, and outlines practical controls for translational researchers—without confusing preclinical findings with clinical proof.

7914 records 1/528 page Next 12345 下5页 Last page